RT Journal Article
T1 Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.
A1 Dávila-Seijo, Paula
A1 Dauden, Esteban
A1 Descalzo, M A
A1 Carretero, Gregorio
A1 Carrascosa, José-Manuel
A1 Vanaclocha, Francisco
A1 Gómez-García, Francisco-José
A1 De la Cueva-Dobao, Pablo
A1 Herrera-Ceballos, Enrique
A1 Belinchón, Isabel
A1 López-Estebaranz, José-Luis
A1 Alsina, Merce
A1 Sánchez-Carazo, José-Luis
A1 Ferrán, Marta
A1 Torrado, Rosa
A1 Ferrandiz, Carlos
A1 Rivera, Raquel
A1 Llamas, Mar
A1 Jiménez-Puya, Rafael
A1 García-Doval, Ignacio
A1 BIOBADADERM Study Group, 
AB Information regarding the safety of biological drugs prescribed to psoriasis patients on daily and long-term bases is insufficient. We used data from the BIOBADADERM registry (Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases) to generate crude rates of infection during therapy with systemic drugs, including biological drugs (infliximab, etanercept, adalimumab, and ustekinumab) and nonbiological drugs (acitretin, cyclosporine, and methotrexate). We also calculated unadjusted and adjusted risk ratios (RRs) (with propensity score adjustment) of infection, serious infections, and recurrent infections of systemic therapies compared with methotrexate, using Poisson regression. Our study included records of 2,153 patients (7,867.5 person-years). The adjusted RR of overall infection was significantly increased in the groups treated with adalimumab with methotrexate (adjusted RR = 2.13, 95% confidence interval [CI] = 1.2-3.7), infliximab (adjusted RR = 1.71, 95% CI = 1.1-2.65), cyclosporine (adjusted RR = 1.58, 95% CI = 1.17-2.15), ustekinumab with methotrexate (adjusted RR = 1.56, 95% CI = 1.08-2.25), and etanercept (adjusted RR = 1.34, 95% CI: 1.02-1.76) compared with methotrexate alone. Cyclosporine had a significant risk of serious infection (adjusted RR = 3.12, 95% CI = 1.1-8.8), followed by adalimumab combined with methotrexate (adjusted RR = 3.28, 95% CI = 0.8-13.5). Adalimumab in combination with methotrexate had the highest risk of infection recurrence (adjusted RR = 4.33, 95% CI = 2.27-8.24).
YR 2016
FD 2016-09-25
LK http://hdl.handle.net/10668/10479
UL http://hdl.handle.net/10668/10479
LA en
DS RISalud
RD Apr 7, 2025